1. Comparison of Calcium Acetate and Sevelamer on Vascular Function and Fibroblast Growth Factor 23 in CKD Patients: A Randomized Clinical Trial 
Mahmut Ilker Yilmaz, MD, Alper Sonmez, MD, Mutlu Saglam, MD, Halil Yaman, MD, Selim Kilic, MD, Tayfun Eyileten, MD, Kayser Caglar, MD, Yusuf Oguz, MD, Abdulgaffar Vural, MD, Mujdat Yenicesu, MD, Francesca Mallamaci, MD, Carmine Zoccali, MD 
American Journal of Kidney Diseases 
Volume 59, Issue 2, Pages (February 2012)
DOI: /j.ajkd
Copyright © 2012 National Kidney Foundation, Inc. Terms and Conditions

2. Figure 1
Flow chart of patients enrolled in the trial. Abbreviations: ACE, angiotensin-converting enzyme [inhibitor]; ARB, angiotensin receptor blocker; CKD, chronic kidney disease.
American Journal of Kidney Diseases  , DOI: ( /j.ajkd )
Copyright © 2012 National Kidney Foundation, Inc. Terms and Conditions

3. Figure 2
Relationships between baseline flow-mediated vasodilatation values with (A) fibroblast growth factor 23 (FGF-23) and (B) serum phosphate (PO4) levels.
American Journal of Kidney Diseases  , DOI: ( /j.ajkd )
Copyright © 2012 National Kidney Foundation, Inc. Terms and Conditions

4. Figure 3
Relationships between changes (delta) in flow-mediated vasodilatation (FMD) and simultaneous changes in fibroblast growth factor 23 (FGF-23) levels in sevelamer- and calcium acetate–treated patients.
American Journal of Kidney Diseases  , DOI: ( /j.ajkd )
Copyright © 2012 National Kidney Foundation, Inc. Terms and Conditions